Symptoms | Frequency (%) |
---|---|
Coughing | 86.1 |
Fever | 85.0 |
Dyspnea | 80.0 |
Ageusia/dygeusia | 57.1 |
Anosmia/hyponosmia | 55,4 |
Mialgia | 34.4 |
Diarrhea | 26.7 |
Nausea/vomiting | 24.4 |
Sore throat | 17.8 |
Cephalea | 16.1 |
Nasal congestion | 16.1 |
Thoracic pain | 15.0 |
Chills | 11.4 |
Abdominal pain | 8.3 |
Sibilance | 6.7 |
Mental and/or confusion alterations | 6.1 |
Eye Manifestation | 4.3 |
Hemoptyse | 0.9 |
PCR | IgM | IgG | Probable clinical response | Observation |
---|---|---|---|---|
- | - | - | Negative | Possibility that the individual has not been infected and is susceptible to the disease. Chances of the individual being infected at the time of testing. |
+/- | - | - | Incubation period of the virus/symptomatic | The body has not yet had time to produce antibodies by the immune system. |
+ | - | - | Immune window | It is not possible to detect the presence of immunoglobulins yet. The individual is probably transmitting the virus at the time of testing. |
+ | + | - | Initial phase of infection | Contact with the virus was recent. The individual is probably transmitting the virus at the time of testing. |
+ | + | + | Active phase of infection | There has been recent infection of the virus and antibodies are already in the transition phase. The individual is probably transmitting the virus at the time of testing |
+ | - | + | Final or late phase/recurrent infection | There has been infection and the individual can still transmit the virus. This result may also show a false negative for IgM. |
- | + | - | Initial phase of disease | Contact with the virus was recent. This result may demonstrate a possible false negative PCR result. |
- | - | + | Serological scar | The individual has been infected by the virus and probably has immunity against the disease and does not transmit the disease. |
- | + | + | Active phase of infection | There has been infection and antibodies are still in the transition phase. This result may demonstrate a possible false negative PCR result. |
• Asymptomatic or pre-symptomatic infection: individuals who tested positive for SARS-CoV-2 but present no symptoms |
• Mild illness: individuals who present any of the various signs or symptoms of COVID-19 (e.g. fever, coughing, sore throat, malaise, headache and myalgia), without dyspnea, tachypnea or altered imaging examinations. |
• Moderate disease: individuals who present evidence of low respiratory disease by clinical evaluation (altered auscultation) or imaging and maintain oxygen saturation (SatO2) > 93%. |
• Severe disease: individuals who have respiratory rate (RR)> 30irpm, SatO2< 93%, oxygenation index (PaO2/FiO2 ratio) <300 or pulmonary infiltrates >50%. |
• Critical illness: individuals who have respiratory failure, septic shock and/or multiple organ dysfunction. |
Corticosteroid | Dosage (mg) |
---|---|
Dexamethasone | 6 |
Hydrocortisone | 50 |
Methylprednisolone | 10 |
Prednisone | 40 |
Analytical alterations and risk factors of severity associated with a worse clinical evolution | |
---|---|
Severity markers | Risk factors for developing serious disease |
Lymphopenia (< 1000) | Age >60 years |
D- Dímer (>1000) | Hypertension |
PCR | Cardiovascular disease |
DHL | Pneumopathy |
Ferritin | Diabetes |
Creatinine | Obesity |
IL-6 (cytokine storm marker) | Immunossuppression |
Increase of transaminases | Cancer Pregnancy |